These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8173194)

  • 21. [Pharmacokinetic comparison of intraperitoneal and intravenous 5-Fu administration].
    Qing SH
    Zhonghua Zhong Liu Za Zhi; 1991 Sep; 13(5):340-2. PubMed ID: 1782844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
    Joulia JM; Pinguet F; Ychou M; Duffour J; Astre C; Bressolle F
    Eur J Cancer; 1999 Feb; 35(2):296-301. PubMed ID: 10448274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer.
    Arbuck SG; Trave F; Douglass HO; Nava H; Zakrzewski S; Rustum YM
    J Clin Oncol; 1986 Oct; 4(10):1510-7. PubMed ID: 3489819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.
    Port RE; Edler L; Herrmann R; Feldmann U
    Ther Drug Monit; 1991 Mar; 13(2):96-102. PubMed ID: 2053130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered plasma kinetics of 5-FU at high dosage in rat and man.
    Schwartz PM; Turek PJ; Hyde CM; Cadman EC; Handschumacher RE
    Cancer Treat Rep; 1985 Jan; 69(1):133-6. PubMed ID: 3967255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration.
    Campora E; Esposito M; Civalleri D; Gogioso L; Decian F; Balletto N; Falcone A; Nobile MT; Parodi B; Cafaggi S
    Anticancer Res; 1987; 7(4B):829-32. PubMed ID: 3674768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of fluorouracil and folinic acid.
    Schalhorn A; Kühl M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):82-92. PubMed ID: 1557660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion.
    Newman EM; Straw JA; Doroshow JH
    Cancer Res; 1989 Oct; 49(20):5755-60. PubMed ID: 2676149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.
    Anderson JH; Kerr DJ; Setanoians A; Cooke TG; McArdle CS
    Br J Cancer; 1992 Jan; 65(1):133-5. PubMed ID: 1733436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system.
    Gyves JW; Ensminger WD; Stetson P; Niederhuber JE; Meyer M; Walker S; Janis MA; Gilbertson S
    Clin Pharmacol Ther; 1984 Jan; 35(1):83-9. PubMed ID: 6690173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
    Reichman B; Markman M; Hakes T; Kemeny N; Kelsen D; Hoskins W; Rubin S; Lewis JL
    J Clin Oncol; 1988 Jan; 6(1):158-62. PubMed ID: 3335888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU.
    Milano G; Roman P; Khater R; Frenay M; Renee N; Namer M
    Int J Cancer; 1988 Apr; 41(4):537-41. PubMed ID: 3356488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of 5-fluorouracil and folinic acid on colonic healing: an experimental study in the rat.
    Graf W; Weiber S; Glimelius B; Jiborn H; Påhlman L; Zederfeldt B
    Br J Surg; 1992 Aug; 79(8):825-8. PubMed ID: 1327397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy.
    Glaholm J; Leach MO; Collins D; al Jehazi B; Sharp JC; Smith TA; Adach J; Hind A; McCready VR; White H
    Br J Radiol; 1990 Jul; 63(751):547-53. PubMed ID: 2390689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salivary passage of 5-fluorouracil during continuous infusion.
    Milano G; Thyss A; Santini J; Frenay M; Francois E; Schneider M; Demard F
    Cancer Chemother Pharmacol; 1989; 24(3):197-9. PubMed ID: 2736710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combinations.
    Danhauser LL; Rustum YM
    J Lab Clin Med; 1979 Jun; 93(6):1047-53. PubMed ID: 438606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose intravenous infusions of 5-fluorouracil for refractory solid tumours-the HI-FU regimen.
    Spiers AS; Kasimis BS; Janis MG
    Clin Oncol; 1980 Mar; 6(1):63-9. PubMed ID: 6154557
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
    Sips JH; van Tellingen O; Nooijen WJ; Rodenhuis S; Ten Bokkel Huinink WJ; Beijnen JH
    Cancer Chemother Pharmacol; 1994; 35(2):144-8. PubMed ID: 7987991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution and toxicity of 5-fluorouracil after intraperitoneal and anal submucosal administration.
    Mossa MA; Osman AM; el-Sayed M; el-Aaser AA; Ismael N; el-Merzabani MM
    J Pharm Belg; 1992; 47(2):129-34. PubMed ID: 1328594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability and feasibility of subcutaneous 5-fluorouracil.
    Borner MM; Kneer J; Crevoisier C; Brunner KW; Cerny T
    Br J Cancer; 1993 Sep; 68(3):537-9. PubMed ID: 8353044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.